|
Age, mean ± SD
|
59 ± 19
|
58 ± 20
|
59 ± 18
|
−0.5355a
|
0.5928
|
|
Gender
| | | |
0.2233b
|
0.6365
|
|
Female
|
140 (57.9)
|
70 (56.0)
|
70 (59.8)
| | |
|
Male
|
102 (42.1)
|
55 (44.0)
|
47 (40.2)
| | |
|
Educational level
| | | |
0.0572b
|
0.9964
|
|
No schooling
|
19 (7.9)
|
10 (8.0)
|
9 (7.7)
| | |
|
Elementary school
|
105 (43.4)
|
54 (43.2)
|
51 (43.6)
| | |
|
High school
|
81 (33.5)
|
43 (34.4)
|
38 (32.5)
| | |
|
Undergraduate
|
33 (13.6)
|
17 (13.6)
|
16 (13.7)
| | |
|
No information
|
4 (1.7)
|
1 (0.8)
|
3 (2.5)
| | |
|
Social status*
| | | |
6.7379b
|
0.08074
|
|
Strata 1 (lowest level)
|
135 (82.3)
|
59 (76.6)
|
76 (87.4)
| | |
|
Strata 2 (low - medium)
|
22 (13.4)
|
12 (15.6)
|
10 (11.5)
| | |
|
Strata 3 (medium)
|
2 (1.2)
|
1 (1.3)
|
1 (1.1)
| | |
|
Strata 6 (highest level)
|
5 (3.1)
|
5 (6.5)
|
0 (0.0)
| | |
|
Teaching hospitals
| | | |
5.1145b
|
0.07752
|
|
Fundacion Cardio Infantil
|
82 (33.9)
|
36 (28.8)
|
46 (39.3)
| | |
|
San Carlos
|
78 (32.2)
|
48 (38.4)
|
30 (25.6)
| | |
|
La Samaritana
|
82 (33.9)
|
41 (32.8)
|
41 (35.1)
| | |
|
No. of hospitalisations, median (IQR, min, max)
|
0 (1, 0, 12)
|
0 (1, 0, 10)
|
0 (1, 0, 12)
|
−0.2168a
|
0.8285
|
|
No. of co-morbidities, median (IQR, min, max)
|
1 (2, 0, 4)
|
1 (2, 0, 4)
|
1 (1, 0, 4)
|
0.4219 a
|
0.6735
|
|
Type of comorbidity
| | | |
11.6316b
|
0.392
|
|
Arthritis/osteoporosis
|
16 (5.5)
|
11 (7.2)
|
5 (3.6)
| | |
|
Malignant diseases
|
12 (4.1)
|
4 (2.6)
|
8 (5.7)
| | |
|
Cardiovascular disorder
|
90 (30.8)
|
47 (30.7)
|
43 (31.0)
| | |
|
Diabetes mellitus
|
22 (7.5)
|
12 (7.9)
|
10 (7.2)
| | |
|
Epilepsy/Parkinson’s disease
|
10 (3.4)
|
7 (4.6)
|
3 (2.2)
| | |
|
Pulmonary disease
|
18 (6.2)
|
13 (8.5)
|
5 (3.6)
| | |
|
Gastrointestinal disease
|
15 (5.2)
|
7 (4.6)
|
8 (5.8)
| | |
|
Hypertension
|
14 (4.8)
|
6 (3.9)
|
8 (5.8)
| | |
|
Hypothyroidism
|
22 (7.5)
|
8 (5.2)
|
14 (10.0)
| | |
|
Metabolism disease
|
18 (6.2)
|
8 (5.2)
|
10 (7.2)
| | |
|
Urinary infection
|
15 (5.1)
|
7 (4.6)
|
8 (5.7)
| | |
|
Other
|
40 (13.7)
|
23 (15.0)
|
17 (12.2)
| | |
|
No. of medicines, median (IQR, min, max)
|
4 (4, 1, 12)
|
4 (4, 1, 16)
|
4 (4, 1, 14)
|
−0.3299a
|
0.7418
|
|
Medicine group
| | | |
17.208b
|
0.3066
|
|
Anti-infective for systemic use
|
39 (3.7)
|
15 (2.8)
|
24 (4.6)
| | |
|
Anti-inflammatory drugs
|
60 (5.6)
|
32 (5.9)
|
28 (5.4)
| | |
|
Cardiovascular system
|
252 (23.6)
|
130 (23.9)
|
122 (23.3)
| | |
|
Alimentary tract and metabolism
|
194 (18.2)
|
102 (18.8)
|
92 (17.6)
| | |
|
Systemic hormonal preparations
|
31 (2.9)
|
12 (2.2)
|
19 (3.6)
| | |
|
Respiratory system
|
65 (6.1)
|
33 (6.1)
|
32 (6.1)
| | |
|
Blood and blood-forming organs
|
93 (8.7)
|
51 (9.4)
|
42 (8.0)
| | |
|
Nervous system
|
168 (15.7)
|
90 (16.5)
|
78 (14.9)
| | |
|
Vitamins and nutrients
|
39 (3.7)
|
21 (3.7)
|
18 (3.4)
| | |
|
Herbal medicine
|
21 (2.0)
|
7 (1.3)
|
14 (2.7)
| | |
|
Over-the-counter medicine
|
75 (7.0)
|
37 (6.8)
|
38 (7.3)
| | |
|
Other
|
30 (2.8)
|
14 (2.6)
|
16 (3.1)
| | |
|
Allergic reaction
| | | |
0b
|
1
|
|
No
|
194 (80.2)
|
100 (80.0)
|
94 (80.3)
| | |
|
Yes
|
48 (19.8)
|
25 (20.0)
|
23 (19.7)
| | |
|
No. of interactions
| | | | | |
|
Minorc, median (IQR, min, max)
|
1 (0, 1, 3)
|
1 (0, 1, 3)
|
1 (0, 1, 2)
|
−0.3943
|
0.6942
|
|
Moderated, median (IQR, min, max)
|
1 (1, 1, 7)
|
1 (1, 1, 7)
|
1 (1, 1, 3)
|
0.9524
|
0.3416
|
|
Majore, median (IQR, min, max)
|
1 (0, 1, 4)
|
1 (0, 1, 2)
|
1 (0, 1, 4)
|
−1.4242
|
0.1787
|
